This company has been marked as potentially delisted and may not be actively trading. (BIOA) (BIOA) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOwnershipTrendsBuy This Stock BIOA vs. RVNC, CKPT, MBX, AVTE, TSVT, SLRN, CYBN, NLTX, PROC, and OPTNShould you be buying (BIOA) stock or one of its competitors? The main competitors of (BIOA) include Revance Therapeutics (RVNC), Checkpoint Therapeutics (CKPT), MBX Biosciences (MBX), Aerovate Therapeutics (AVTE), 2seventy bio (TSVT), Acelyrin (SLRN), Cybin (CYBN), Neoleukin Therapeutics (NLTX), Procaps Group (PROC), and OptiNose (OPTN). These companies are all part of the "pharmaceutical preparations" industry. (BIOA) vs. Its Competitors Revance Therapeutics Checkpoint Therapeutics MBX Biosciences Aerovate Therapeutics 2seventy bio Acelyrin Cybin Neoleukin Therapeutics Procaps Group OptiNose (BIOA) (NYSE:BIOA) and Revance Therapeutics (NASDAQ:RVNC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, profitability, dividends, valuation and analyst recommendations. Which has preferable valuation & earnings, BIOA or RVNC? (BIOA) has higher earnings, but lower revenue than Revance Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio(BIOA)N/AN/AN/AN/AN/ARevance Therapeutics$234.04M1.63-$323.99M-$1.93-1.89 Do institutionals and insiders believe in BIOA or RVNC? 97.7% of Revance Therapeutics shares are owned by institutional investors. 5.1% of Revance Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media prefer BIOA or RVNC? In the previous week, (BIOA)'s average media sentiment score of 0.00 equaled Revance Therapeutics'average media sentiment score. Company Overall Sentiment (BIOA) Neutral Revance Therapeutics Neutral Is BIOA or RVNC more profitable? (BIOA) has a net margin of 0.00% compared to Revance Therapeutics' net margin of -74.67%. Company Net Margins Return on Equity Return on Assets (BIOA)N/A N/A N/A Revance Therapeutics -74.67%N/A -37.22% Do analysts prefer BIOA or RVNC? (BIOA) currently has a consensus price target of $5.67, indicating a potential upside of 24.00%. Revance Therapeutics has a consensus price target of $8.45, indicating a potential upside of 131.51%. Given Revance Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Revance Therapeutics is more favorable than (BIOA).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score (BIOA) 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75Revance Therapeutics 0 Sell rating(s) 7 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.13 SummaryRevance Therapeutics beats (BIOA) on 6 of the 8 factors compared between the two stocks. Get (BIOA) News Delivered to You Automatically Sign up to receive the latest news and ratings for BIOA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BIOA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BIOA vs. The Competition Export to ExcelMetric(BIOA)Pharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$161.32M$838.34M$5.56B$20.64BDividend YieldN/A4.84%5.06%3.72%P/E RatioN/A1.3828.2627.83Price / SalesN/A241.37427.7042.22Price / CashN/A17.6937.1222.32Price / BookN/A6.588.044.57Net IncomeN/A-$23.83M$3.19B$989.30M (BIOA) Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BIOA(BIOA)N/A$4.57-1.5%$5.67+24.0%+35,603.1%$161.32MN/A0.00N/ARVNCRevance Therapeutics2.6351 of 5 stars$3.65flat$8.45+131.5%N/A$381.02M$234.04M-1.89500CKPTCheckpoint Therapeutics0.4502 of 5 stars$4.26flat$4.33+1.7%N/A$370.71M$41K-2.3210MBXMBX Biosciences1.7077 of 5 stars$11.41+6.1%$37.50+228.7%N/A$359.31MN/A0.0036AVTEAerovate TherapeuticsN/A$9.19-0.6%N/A-84.5%$266.37MN/A-3.0720High Trading VolumeTSVT2seventy bioN/A$5.00flat$5.00N/A$266.15M$48.37M-2.69440SLRNAcelyrinN/A$2.27flat$9.60+322.9%N/A$229.17MN/A-0.92135CYBNCybin2.7391 of 5 stars$8.39+2.9%$86.00+925.0%N/A$193.17MN/A-1.9250Analyst ForecastNLTXNeoleukin TherapeuticsN/A$16.16-2.5%N/A-49.7%$151.87MN/A-5.2090High Trading VolumePROCProcaps GroupN/A$0.95-40.3%N/A-62.0%$107.18M$409.92M0.004,900Gap DownHigh Trading VolumeOPTNOptiNose0.6559 of 5 stars$9.60flat$9.00-6.3%N/A$97.22M$81.86M-2.29190 Related Companies and Tools Related Companies Revance Therapeutics Alternatives Checkpoint Therapeutics Alternatives MBX Biosciences Alternatives Aerovate Therapeutics Alternatives 2seventy bio Alternatives Acelyrin Alternatives Cybin Alternatives Neoleukin Therapeutics Alternatives Procaps Group Alternatives OptiNose Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:BIOA) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding (BIOA) Please log in to your account or sign up in order to add this asset to your watchlist. Share (BIOA) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
